A Phase 2 interventional study of Ranibizumab and ABBV-RGX-314 Dose 1 in Neovascular Age-Related Macular Degeneration (nAMD), sponsored by AbbVie. Active, not recruiting at 18 sites in United States. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Macular Degeneration by AbbVie — 3 open to participants now, 6 under way, 3 of them phase 3. Macular Degeneration · AbbVie.
Among the 22 studies in Macular Degeneration by AbbVie, this one is the 9th largest by enrollment, is one of 2 that started in 2020, is one of 12 in phase 2, and was the 17th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 22 studies in Macular Degeneration by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Austria, Belgium and 14 more countries
Ages 50+
AbbVie · Sites in United States
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 5
First in 2004; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 122 across the 22 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
1 of the studies in Macular Degeneration by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Macular Degeneration by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). The typical treatment for nAMD is frequent injections of anti-VEGF therapy. Researchers are testing ABBV-RGX-314 to see if it has similar effects as the current approved standard of care, such as Lucentis® or Eylea® injections.
The duration of this study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314 after week 52, up to 80 weeks post-randomization.
The primary outcome measure for this investigational study is to evaluate the mean change in best-corrected visual acuity (BCVA) for ABBV-RGX-314 compared with ranibizumab monthly at the Week 40 visit.
This phase 2, randomized, dose-escalation study is designed to evaluate the efficacy, safety and tolerability of ABBV-RGX-314 gene therapy in subjects with nAMD.
ABBV-RGX-314 will be injected into the SCS part of the eye. Approximately 140 participants who meet the inclusion/exclusion criteria will be enrolled into one of 7 cohorts. Participants will be randomized in Cohorts 1 and 2 to receive ABBV-RGX-314 or the intravitreal ranibizumab control. Participants enrolled in Cohorts 3 through 5 will receive ABBV-RGX-314. Participants enrolled in Cohort 6 will receive ABBV-RGX-314 and will be randomized to one of two different post-procedural steroid regimens. Participants randomized in Cohort 7 will receive ABBV-RGX-314 with a protocol mandated steroid regimen or the intravitreal ranibizumab control. Cohort 1 will evaluate ABBV-RGX-314 Dose 1, Cohorts 2 and 3 will evaluate ABBV-RGX-314 Dose 2, Cohorts 4, 5, and 6 will evaluate ABBV-RGX-314 Dose 3, and Cohort 7 will evaluate ABBV-RGX-314 Dose 4.
The duration of the study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314, up to 80 weeks post-randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
COHORT 6 AND 7 ONLY:
Note: Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control treatment arm
Biological: Ranibizumab
ABBV-RGX-314 Dose 1
Genetic: ABBV-RGX-314 Dose 1
ABBV-RGX-314 Dose 2
Genetic: ABBV-RGX-314 Dose 2
ABBV-RGX-314 Dose 3
Genetic: ABBV-RGX-314 Dose 3
ABBV-RGX-314 Dose 3 and Local Steroid
Genetic: ABBV-RGX-314 Dose 3 · Drug: Local Steroid
ABBV-RGX-314 Dose 3 and Topical Steroid
Genetic: ABBV-RGX-314 Dose 3 · Drug: Topical Steroid
ABBV-RGX-314 Dose 4 and Topical Steroid
Drug: Topical Steroid · Genetic: ABBV-RGX-314 Dose 4
Ranibizumab (anti-VEGF agent)
AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
Also known as: Combination Product
AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
Also known as: Combination Product
AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
Also known as: Combination Product
Local steroid
Topical steroid
AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
Also known as: Combination Product
Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score
The scale used is the early treatment diabetic retinopathy study (ETDRS) letter score from 0-100 and higher score being better vision.
Time frame: 40 weeks
Incidence of overall and ocular adverse events (AEs) and serious adverse events (SAEs)
Incidence of overall and ocular adverse events (AEs) and serious adverse events (SAEs)
Time frame: 52 weeks
Vector shedding analysis in serum, urine, and tears
Evaluate the safety and tolerability of ABBV-RGX-314
Time frame: 52 Weeks
Proportion of participants who experience ocular inflammation following SCS ABBV-RGX-314 administration
To evaluate the incidences of ocular inflammation following SCS ABBV-RGX-314 administration
Time frame: 52 weeks
Mean change from baseline in choroidal neovascularization (CNV) lesion size and leakage area based on fluorescein angiography (FA)
To evaluate the effect of ABBV-RGX-314 on CNV lesion growth and leakage as measured by FA
Time frame: Up to Week 80
Mean change from baseline in BCVA based on ETDRS score
Evaluate the effect of ABBV-RGX-314 on BCVA
Time frame: Up to Week 80
Proportion of participants (1) gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 letters; (2) losing ≥ 15, ≥ 10, ≥ 5, or > 0 letters (3) maintaining vision (not losing ≥ 15 letters) compared with baseline as per BCVA
To evaluate the effect of ABBV-RGX-314 on BCVA
Time frame: Up to Week 52
Mean change from baseline in CRT as measured by SD-OCT
To evaluate the effect of ABBV-RGX-314 on CRT, as measured by SD-OCT
Time frame: Up to Week 80
Mean supplemental anti-VEGF injection annualized rate in the ABBV-RGX-314 treatment arms
To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment
Time frame: Up to Week 80
Proportion of participants who have a reduction of ≥ 50% and ≥ 75% in supplemental anti-VEGF- injection annualized rate
Proportion of participants who have a reduction of ≥ 50% and ≥ 75% in supplemental anti-VEGF- injection annualized rate through Week 40 and Week 52 compared with the prior 52 weeks preceding the first intravitreal ranibizumab injection received as part of the Screening Period (ABBV-RGX-314 administered participants)
Time frame: 52 Weeks
Proportion of participants with 0, ≤ 1, and ≤ 2 supplemental injections
To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment
Time frame: Up to Week 80
Mean percent reduction in supplemental anti-VEGF injection annualized rate
To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment
Time frame: Up to Week 80
Time from ABBV-RGX-314 administration to first supplemental anti-VEGF injection
To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment
Time frame: 80 Weeks
Aqueous humor ABBV-RGX- 314 TP concentration over time
To evaluate the concentration of ABBV-RGX-314 TP in aqueous humor and serum
Time frame: 52 Weeks
Mean change from baseline in serum ABBV-RGX-314 TP concentration over time
To evaluate the concentration of ABBV-RGX-314 TP in aqueous humor and serum
Time frame: 80 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Oct 2026, 73 months.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 73 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Steroids